- Teva launches authorized generic version of Pfizer's Detrol LA
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Teva launches generic drug for cystic fibrosis patients
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- Generic drug prices spike, but PBMs' reimbursement rates don't keep up, NCPA study finds
JERUSALEM Teva Pharmaceutical Industries got closer to finishing its $5 billion acquisition of German drug maker Ratiopharm from the Merckle Group, the Israeli generic drug manufacturer said Tuesday.
Teva announced that the European Commission approved its plan to acquire Ratiopharm. The Competition Bureau of Canada had said Friday that it would not challenge the acquisition.
Ratiopharm was put up for sale last year following the suicide of its owner, Adolf Merckle, who left behind crushing debts for the generic drug maker and Phoenix Pharmahandel & Co., the family’s drug-distribution business.